4D Molecular Therapeutics annual operating margin
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Operating Margin Growth & History (FDMT)
4D Molecular Therapeutics's operating margin was −187.24% for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −187.24% | +507491.14 pp |
| 2024 | 2024-12-31 | −507,678.38% | −507133.73 pp |
| 2023 | 2023-12-31 | −544.65% | +2971.88 pp |
| 2022 | 2022-12-31 | −3,516.52% | −3121.06 pp |
| 2021 | 2021-12-31 | −395.46% | +28.58 pp |
| 2020 | 2020-12-31 | −424.04% | +305.33 pp |
| 2019 | 2019-12-31 | −729.37% | — |
4D Molecular Therapeutics quarterly operating margin
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2,037.16% | +394336.17 pp |
| Q1 2026 | 2026-03-31 | −2,416.15% | +380591.00 pp |
| Q4 2025 | 2025-12-31 | 17.29% | +5611717.29 pp |
| Q3 2025 | 2025-09-30 | −67,983.33% | +1636416.67 pp |
| Q2 2025 | 2025-06-30 | −396,373.33% | +452746.67 pp |
| Q1 2025 | 2025-03-31 | −383,007.14% | −246807.14 pp |
| Q4 2024 | 2024-12-31 | −5,611,700.00% | — |
| Q3 2024 | 2024-09-30 | −1,704,400.00% | −1704330.84 pp |
| Q2 2024 | 2024-06-30 | −849,120.00% | −835673.97 pp |
| Q1 2024 | 2024-03-31 | −136,200.00% | −126097.32 pp |
| Q3 2023 | 2023-09-30 | −69.16% | +5229.84 pp |
| Q2 2023 | 2023-06-30 | −13,446.03% | +4100.89 pp |
| Q1 2023 | 2023-03-31 | −10,102.68% | −7937.63 pp |
| Q4 2022 | 2022-12-31 | −2,301.20% | +24616.19 pp |
| Q3 2022 | 2022-09-30 | −5,299.00% | −3640.07 pp |
| Q2 2022 | 2022-06-30 | −17,546.91% | −17494.81 pp |
| Q1 2022 | 2022-03-31 | −2,165.05% | −1349.45 pp |
| Q4 2021 | 2021-12-31 | −26,917.39% | — |
| Q3 2021 | 2021-09-30 | −1,658.93% | −1553.61 pp |
| Q2 2021 | 2021-06-30 | −52.10% | +379.74 pp |
| Q1 2021 | 2021-03-31 | −815.60% | −426.36 pp |
| Q3 2020 | 2020-09-30 | −105.32% | — |
| Q2 2020 | 2020-06-30 | −431.84% | — |
| Q1 2020 | 2020-03-31 | −389.24% | — |
4D Molecular Therapeutics operating margin trends
Over the last five fiscal years, 4D Molecular Therapeutics's operating margin increased from −424.04% to −187.24%, a change of +236.79 percentage points. The latest reported quarter, Q2 2026, shows −2,037.16%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗